Business
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid as a first-line, evidence-based therapy for LDL-C lowering for patients on maximally tolerated statins in the 2025 American College of Cardiology (ACC) Scientific Statement on Management of Peripheral Artery Disease (PAD)
About this update from Esperion Therapeutics, Inc.
[{"type":"image","alt":"Esperion Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Esperion Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/4890074d6b0f0d0a38002f9d11a84e21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l5dS5p4arlgcAzQpBUpJMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4890074d6b0f0d0a38002f9d11a84e21","width":300,"height":94}},"lazy":false},{"type":"text","content":"– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits –","length":166,"tagName":"p"},{"type":"text","content":"ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid as a first-line, evidence-based therapy for LDL-C lowering for patients on maximally tolerated statins in the 2025 American College of Cardiology (ACC) Scientific Statement on Management of Peripheral Artery Disease (PAD) in Adults with Diabetes.","length":363,"tagName":"p"},{"type":"text","content":"“We recognize the significance of the American College of Cardiology’s scientific statement highlighting the importance of aggressive LDL-C lowering in patients with diabetes and peripheral artery disease. The inclusion of bempedoic acid reinforces its important role as a proven, evidence-based therapy for reducing both cardiovascular and limb risk in high-risk populations,” said Sheldon Koenig, CEO of Esperion.","length":415,"tagName":"p"},{"type":"text","content":"”This statement provides clinicians with valuable insight to help close treatment gaps. This scientific statement reinforces the valuable role bempedoic acid plays in cardiovascular risk reduction. As we anticipate the forthcoming U.S. dyslipidemia treatment guidelines from ACC/American Heart Association (AHA) in early 2026, it also strengthens our confidence that bempedoic acid will be included in those recommendations, consistent with its prominent endorsement in the European guidelines issued in August,” concluded Koenig.","length":530,"tagName":"p"},{"type":"text","content":"Key ACC Recommendations for LDL-C Lowering in Adults with PAD and Diabetes","length":74,"tagName":"p"},{"type":"list","items":[{...